Schimmer Aaron D
Princess Margaret Hospital, 610 University Ave, Toronto, ON, Canada M5G 2M9.
Best Pract Res Clin Haematol. 2008 Mar;21(1):5-11. doi: 10.1016/j.beha.2007.11.002.
Knowledge about apoptosis pathways developed in the last few years is already being translated into novel targeted therapies. Two illustrative approaches to this process are the development of small molecule BCL2 inhibitors and X-linked inhibitors of apoptosis proteins (XIAP) inhibitors. This work demonstrates both the development of new agents based on molecular mechanisms and how these agents further our understanding of the biology of apoptosis.
过去几年中有关凋亡途径的知识已转化为新型靶向疗法。针对这一过程的两种典型方法是小分子BCL2抑制剂和X连锁凋亡蛋白（XIAP）抑制剂的研发。这项工作展示了基于分子机制的新药物研发过程，以及这些药物如何进一步加深我们对凋亡生物学的理解。
